Through this study, we are able to show, for the first time, that GSK-3β inhibition induced-TFEB translocation and subsequent biogenesis of functional lysosomes is associated with the induction of c-FLIPL degradation, thus defines a novel cellular process induced by GSK-3β inhibitors in the HCC treatment. This evidence concerns the gene CFLAR and hepatocellular carcinoma.